Findings

What do systematic reviews say?

25 questions · 25 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 24%GRADE not reported 1 · 4%Very low 16 · 64%Low 2 · 8%Moderate 0 · 0%High 0 · 0%

RISPERIDONE vs CLOZAPINE ‐ all data short term

Subjective well‐being · people with both severe mental illness and substance misuse

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

RISPERIDONE vs CLOZAPINE ‐ all data short term

Craving · people with both severe mental illness and substance misuse

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

RISPERIDONE vs CLOZAPINE ‐ all data short term

Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse

It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 4.05 [0.21, 78.76]
1 study · 36 participants
Very low

RISPERIDONE vs CLOZAPINE ‐ all data short term

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse

It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 2.71 [0.3, 24.08]
2 studies · 50 participants
Very low

RISPERIDONE vs CLOZAPINE ‐ all data short term

Leaving the study early · people with both severe mental illness and substance misuse

It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 0.49 [0.1, 2.51]
2 studies · 45 participants
Very low